Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Stereotactic Radiotherapy in Oligometastatic Brain Disease: a Randomised Phase III Study Comparing Hypofractionated Stereotactic Radiation Therapy (3*10 Gy) to the Historical Single-dose Radiosurgery (1*20 to 25 Gy) With Medico-economic Evaluation.

NCT05102747 is registered in ClinicalTrials.gov with Centre Francois Baclesse as lead sponsor.

NCT NCT05102747
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05102747 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Stereotactic Radiotherapy in Oligometastatic Brain Disease: a Randomised Phase III Study Comparing Hypofractionated Stereotactic Radiation Therapy (3*10 Gy) to the Historical Single-dose Radiosurgery (1*20 to 25 Gy) With Medico-economic Evaluation.
Lead sponsor
Centre Francois Baclesse
Phase
Not applicable
Overall status
Recruiting
Start date
January 12, 2023
Completion date
January 31, 2031
Enrollment
504 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastasis, oligoprogression